| Title |
Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease
|
|---|---|
| Published in |
Digestive Diseases and Sciences, July 2000
|
| DOI | 10.1023/a:1005588911207 |
| Pubmed ID | |
| Authors |
Mario Guslandi, Gianni Mezzi, Massimo Sorghi, Pier Alberto Testoni |
| Abstract |
The possible role of Saccharomyces boulardii, a nonpathogenic yeast with beneficial effects on the human intestine, in the maintenance treatment of Crohn's disease has been evaluated. Thirty-two patients with Crohn's disease in clinical remission (CDAI < 150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily. Clinical relapses as assessed by CDAI values were observed in 37.5% of patients receiving mesalamine alone and in 6.25% of patients in the group treated with mesalamine plus the probiotic agent. Our results suggest that Saccharomyces boulardii may represent a useful tool in the maintenance treatment of Crohn's disease. However, in view of the product's cost, further controlled studies are needed to confirm these preliminary data. |
Mendeley readers
The data shown below were compiled from readership statistics for 264 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| Italy | 1 | <1% |
| Brazil | 1 | <1% |
| United Kingdom | 1 | <1% |
| Spain | 1 | <1% |
| Unknown | 259 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 40 | 15% |
| Student > Bachelor | 39 | 15% |
| Student > Ph. D. Student | 35 | 13% |
| Researcher | 30 | 11% |
| Student > Postgraduate | 20 | 8% |
| Other | 41 | 16% |
| Unknown | 59 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 60 | 23% |
| Medicine and Dentistry | 54 | 20% |
| Biochemistry, Genetics and Molecular Biology | 24 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 4% |
| Nursing and Health Professions | 9 | 3% |
| Other | 35 | 13% |
| Unknown | 72 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2020.
All research outputs
#2,087,593
of 25,374,647 outputs
Outputs from Digestive Diseases and Sciences
#223
of 4,668 outputs
Outputs of similar age
#1,552
of 39,276 outputs
Outputs of similar age from Digestive Diseases and Sciences
#1
of 11 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,668 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 39,276 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.